Steven Shallcross, Theriva Biologics CEO and CFO

Syn­thet­ic com­pletes trans­for­ma­tion with new name and can­cer-killing virus fo­cus

Just over a year ago, as Syn­thet­ic Bi­o­log­ics strug­gled to find cash for its C. dif­fi­cile can­di­date, the team de­cid­ed it was time for a rein­ven­tion. They’ve since snapped up an on­colyt­ic virus play­er and shift­ed the fo­cus to can­cer — and on Wednes­day, they com­plet­ed the fi­nal stage of trans­for­ma­tion.

Syn­thet­ic changed its name to Theri­va Bi­o­log­ics, a mashup of the words “ther­a­peu­tics,” “in­tra­venous,” and “virus” or “ade­n­ovirus,” the com­pa­ny an­nounced. Gone is the old or­ange lo­go, re­placed by a “re­fresh­ing” and “calm” blue and green col­or scheme, CEO and CFO Steven Shall­cross told End­points News. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.